Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaDavid S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumorsAnthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget|September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Pageof 8